Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,315 questions · 23,557 findings · 2,311 reviews

No studies found 4,183 · 17.8%GRADE not reported 3,930 · 16.7%Very low 5,371 · 22.8%Low 5,787 · 24.6%Moderate 3,320 · 14.1%High 966 · 4.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal stroke Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Doubling of SCr Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).

1 finding from 1 review